This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.
To asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
436
Co-Primary Outcome: Percent Change in Body Weight
Percent change in body weight from Baseline to Day 171 is presented.
Time frame: Baseline to Day 171
Co-Primary Outcome: Percentage of Subjects Who Achieve Body Weight Loss ≥ 5%
Percentage of participants who achieve a body weight loss ≥ 5% from Baseline to Day 171 is presented.
Time frame: Baseline to Day 171
Percent Body Weight Change in Subjects With Impaired Plasma Glucose Status at Baseline
Impaired plasma glucose status is defined as Fasting Plasma Glucose (FPG) ≥100mg/dL and \<126mg/dL at baseline measurement.
Time frame: Baseline to Day 171
Change in Plasma Glucose Status (Normal, Impaired, Diabetic) in Subjects With Impaired Plasma Glucose Status at Baseline.
Normal plasma glucose status is defined FPG ≤ 100mg/dL. Impaired plasma glucose status is defined as FPG ≥100mg/dL and \<126mg/dL. Diabetic plasma glucose status was defined as FPG \>126mg/dL.
Time frame: Baseline to Day 171
Percent Change in Plasma Glucose
Percent change in Plasma Glucose in subjects with impaired glucose and T2D at baseline. Impaired plasma glucose is defined as FPG≥100mg/dL and FPG\<126mg/dL.
Time frame: Baseline to Day 171
Change in Body Mass Index (BMI)
The BMI was calculated using height (in cm) and weight (in kg) according to the following formula: BMI (kg/m2((superscript 1)) = Weight (kg)/\[Height (cm)/100\]2(superscript2).
Time frame: Baseline to Day 171
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Investigative Site
Anaheim, California, United States
Investigative Site
San Diego, California, United States
Investigative Site
Tustin, California, United States
Investigative Site
Walnut Creek, California, United States
Investigative Site
West Hills, California, United States
Investigative Site
Aurora, Colorado, United States
Investigative Site
Jacksonville, Florida, United States
Investigative Site
Miami, Florida, United States
Investigative Site
Boise, Idaho, United States
Investigative Site
Chicago, Illinois, United States
...and 26 more locations
Change in Hemoglobin HbA1c in Subjects With Type 2 Diabetes at Baseline
To assess the decrease in HbA1c after repeated administration of Gelesis 100 over a period of 168 days in overweight and obese people with type 2 diabetes, The glycosylated hemoglobin was measured in mmol/mol.
Time frame: Baseline to Day 171